Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine and Milton S. Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA.
Biochem Pharmacol. 2013 Sep 15;86(6):726-33. doi: 10.1016/j.bcp.2013.06.032. Epub 2013 Jul 12.
The current study reports a previously unappreciated role of Sirtuin 3 (SIRT3), a mitochondrial protein deacetylase, in altering sensitivity of breast cancer cells to tamoxifen (Tam), a commonly used anti-estrogen agent. We showed that SIRT3 was significantly up-regulated at both mRNA and protein levels in the Tam-resistance human breast cancer cell line MTR-3, which was derived from MCF-7 line by continuous selective culture in the presence of 1μM of Tam for two years. We further demonstrated that SIRT3 was rapidly up-regulated in the sensitive MCF-7 cells following exposure to Tam. Transfection of MCF-7 cells with a SIRT3 expression plasmid decreased cellular sensitivity to Tam and blocked the Tam-induced apoptosis. Furthermore, silencing of SIRT3 expression in MTR-3 cells sensitized the resistant cells to Tam and enhanced apoptotic cell death. MTR-3 cells with silencing of SIRT3 expression showed increases in the mitochondrial content of ERβ, ROS level and apoptosis. These results not only uncovered a new role for SIRT3 in cancer but also identified this mitochondrial protein deacetylase as a previously unrecognized factor that participates in regulation of Tam sensitivity in breast cancer cells. Thus, SIRT3 might be considered as a potential target for overcoming Tam resistance in treatment of breast cancer.
本研究报告了 Sirtuin 3(SIRT3)的一个以前未被重视的作用,它是一种线粒体蛋白去乙酰化酶,可改变乳腺癌细胞对他莫昔芬(Tam)的敏感性,Tam 是一种常用的抗雌激素药物。我们发现,在 Tam 耐药的人乳腺癌细胞系 MTR-3 中,SIRT3 的 mRNA 和蛋白水平均显著上调,该细胞系是从 MCF-7 细胞系通过连续两年在 1μM Tam 存在下选择性培养而获得的。我们进一步证明,在敏感的 MCF-7 细胞中,暴露于 Tam 后 SIRT3 迅速上调。用 SIRT3 表达质粒转染 MCF-7 细胞可降低细胞对 Tam 的敏感性,并阻止 Tam 诱导的细胞凋亡。此外,沉默 MTR-3 细胞中的 SIRT3 表达可使耐药细胞对 Tam 敏感,并增强细胞凋亡。沉默 SIRT3 表达的 MTR-3 细胞中线粒体 ERβ 含量增加、ROS 水平升高和细胞凋亡增加。这些结果不仅揭示了 SIRT3 在癌症中的新作用,还鉴定了这种线粒体蛋白去乙酰化酶作为一个以前未被识别的因子,参与调节乳腺癌细胞对 Tam 的敏感性。因此,SIRT3 可能被认为是克服乳腺癌治疗中 Tam 耐药的潜在靶标。